Revance Therapeutics, Inc. with ticker code (RVNC) now have 12 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between 65 and 21 with the average target price sitting at $39.42. Given that the stocks previous close was at $31.82 and the analysts are correct then there would likely be a percentage uptick in value of 23.9%. The 50 day MA is $32.37 and the 200 day MA is $27.22. The market cap for the company is 2.73B. The stock price for Skyline Champion Corporation is 32.51 USD
The potential market cap would be $3,384,710,397 based on the market consensus.
USD
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of 2.06 and a -28.21% return on assets.
